Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.

Commercially available St. John's wort (Hypericum perforatum) extracts, preparations that are used in the treatment of depression, were examined for the potential to inhibit human cytochrome P450 (CYP) enzyme activities, specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Crude extracts demonstrated inhibition of each of these five enzymes, with CYP2D6, CYP2C9, and CYP3A4 being more sensitive than CYP1A2 and CYP2C19. Extracts were fractionated by HPLC, and each of the fractions was tested for inhibition of these five CYPs to identify individual constituents with inhibitory activity. Several fractions were shown to possess inhibitory activity, including the fractions containing hyperforin (the putative active antidepressant constituent), I3,II8-biapigenin, and hypericin. Hyperforin and I3,II8-biapigenin were isolated from the extract, and inhibition constants for the five CYP activities were measured. In addition, three other constituents, hypericin, quercetin, and chlorogenic acid, were tested for inhibitory activity toward the CYP enzymes. The flavonoid compound I3,II8-biapigenin was shown to be a potent, competitive inhibitor of CYP3A4, CYP2C9, and CYP1A2 activities with K(i) values of 0.038, 0.32, and 0.95 microM, respectively. Hyperforin was a potent noncompetitive inhibitor of CYP2D6 activity (K(i) = 1.5 microM) and competitive inhibitor of CYP2C9 and CYP3A4 activities (K(i) = 1.8 and 0.48 microM, respectively). Hypericin also demonstrated potent inhibition of several CYP activities. These in vitro data indicate that St. John's wort preparations contain constituents that can potently inhibit the activities of major human drug-metabolizing enzymes and suggest that these preparations should be examined for potential pharmacokinetic drug interactions in vivo.

[1]  K. Pang,et al.  Synthesis of singly 2H‐, 3H‐, and 14C‐ and doubly labeled acetaminophen, phenacetin, and p‐acetanisidine , 1982 .

[2]  M Kieser,et al.  St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. , 1998, Pharmacopsychiatry.

[3]  W. Müller,et al.  Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  C. Erdelmeier.  Hyperforin, Possibly the Major Non-Nitrogenous Secondary Metabolite of Hypericum perforatum L. , 1998, Pharmacopsychiatry.

[5]  D. Bailey,et al.  Grapefruit juice-drug interactions. , 1998, British journal of clinical pharmacology.

[6]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[7]  C. Yoon,et al.  Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.

[8]  P. Schmidt,et al.  Isolation, Purity Analysis and Stability of Hyperforin as a Standard Material from Hypericum perforatum L. , 1999, The Journal of pharmacy and pharmacology.

[9]  F. Panzeri,et al.  Identification by high-performance liquid chromatography–diode array detection–mass spectrometry and quantification by high-performance liquid chromatography–UV absorbance detection of active constituents of Hypericum perforatum , 1998 .

[10]  P. Watkins,et al.  6′,7′‐Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P‐glycoprotein , 1999, Clinical pharmacology and therapeutics.

[11]  A. Y. Lu,et al.  Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.

[12]  A. Nahrstedt,et al.  Biologically Active and Other Chemical Constituents of the Herb of Hypericum perforatum L. , 1997, Pharmacopsychiatry.

[13]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[14]  S. Zhai,et al.  Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[15]  S. Zhai,et al.  COMPARATIVE INHIBITION OF HUMAN CYTOCHROMES P 450 1 A 1 AND 1 A 2 BY FLAVONOIDS , 1998 .

[16]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[17]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[18]  R. Tackett,et al.  St. John's wort: a new alternative for depression? , 1999, International journal of clinical pharmacology and therapeutics.

[19]  S. Chatterjee,et al.  Oral Bioavailability of Hyperforin from Hypericum Extracts in Rats and Human Volunteers , 1998, Pharmacopsychiatry.

[20]  I. Roots,et al.  Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.

[21]  S. Risch,et al.  Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.

[22]  W. Pryor.  Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[23]  J. Hölzl,et al.  Biflavonoids in Hypericum perforatum 1; Part 1. Isolation of I3, II8-Biapigenin , 1987, Planta medica.